Trevena Inc (OQ:TRVN)

Jan 01, 2024 11:37 am ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action – ILMN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Illumina, Inc. (NASDAQ: ILMN) between May 1, 2023 and October 16, 2023, both dates inclusive (the “Class Period”), of the important January 9, 2024 lead...
Dec 28, 2023 02:00 pm ET
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has closed...
Dec 27, 2023 09:10 am ET
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered...
Dec 04, 2023 07:02 am ET
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 62nd Annual Meeting...
Dec 04, 2023 07:00 am ET
Trevena Awarded OLINVYK Agreement with Premier, Inc.
Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for...
Nov 30, 2023 07:00 am ET
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced today the acceptance of an abstract based on the...
Nov 14, 2023 07:00 am ET
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended...
Nov 09, 2023 07:00 am ET
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Oct 16, 2023 07:00 am ET
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported topline safety and tolerability data for the two...
Oct 02, 2023 07:00 am ET
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced completion of initial analysis of OLINVYK...
Sep 11, 2023 09:31 am ET
Thinking about buying stock in Plus Therapeutics, BioLine RX, Flora Growth, Emx Royalty, or Trevena?
NEW YORK, Sept. 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTV, BLRX, FLGC, EMX, and TRVN.
Sep 06, 2023 07:01 am ET
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of a $15 million tranche under its...
Sep 06, 2023 07:00 am ET
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced preliminary topline data from two Phase 1...
Aug 14, 2023 07:00 am ET
Trevena Reports Second Quarter 2023 Results and Provides Business Update
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter...
Jul 20, 2023 07:00 am ET
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to...
Jun 26, 2023 07:00 am ET
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced new topline OLINVYK data from the ARTEMIS study....
May 31, 2023 07:00 am ET
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received a $3 million milestone...
May 30, 2023 07:00 am ET
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing...
May 15, 2023 07:00 am ET
Trevena Reports First Quarter 2023 Results and Provides Business Update
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter ended...
May 09, 2023 07:00 am ET
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
May 08, 2023 07:00 am ET
Trevena Announces Approval of OLINVYK in China
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that its partner in China, Jiangsu Nhwa,...
May 03, 2023 07:00 am ET
Trevena to Participate in Three Upcoming Conferences
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that members of Management will participate in...
Mar 30, 2023 07:02 am ET
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced initial topline OLINVYK data from two related...
Mar 30, 2023 07:00 am ET
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter...
Mar 27, 2023 07:00 am ET
Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Mar 07, 2023 07:00 am ET
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a Phase 1 proof-of-concept...
Feb 14, 2023 08:00 am ET
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of OLINVYK data in the...
Jan 09, 2023 07:00 am ET
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the enrollment of the first subject in a Phase 1...
Dec 08, 2022 07:00 am ET
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that three abstracts related to the Company’s...
Nov 29, 2022 07:00 am ET
Trevena Regains Compliance with Nasdaq Listing Requirements
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing...
Nov 16, 2022 08:00 am ET
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered...
Nov 09, 2022 04:01 pm ET
Trevena Announces Reverse Stock Split
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to...
Nov 09, 2022 07:02 am ET
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced positive clinical data for TRV045, its selective...
Nov 09, 2022 07:00 am ET
Trevena Reports Third Quarter 2022 Results and Provides Business Update
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended...
Nov 07, 2022 07:00 am ET
Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Oct 24, 2022 07:00 am ET
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that an abstract entitled, “A Randomized...
Sep 07, 2022 07:00 am ET
Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference
Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company will present a corporate overview at...
Aug 11, 2022 07:00 am ET
Trevena Reports Second Quarter 2022 Results and Provides Business Update
Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter ended...
Aug 08, 2022 07:00 am ET
Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Jul 29, 2022 05:27 pm ET
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock
Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the closing of its...
Jul 29, 2022 08:00 am ET
Trevena, Inc. Announces Registered Direct Offering of Preferred Stock
Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered...
Jul 28, 2022 07:00 am ET
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update
Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported positive topline results from its post-approval...
Jun 14, 2022 07:00 am ET
Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication in Expert Review of...
Jun 10, 2022 07:00 am ET
Trevena to Participate at the JMP Securities Life Sciences Conference
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, and Mark...
May 18, 2022 04:05 pm ET
Trevena to Present at the H.C. Wainwright Global Investment Conference
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry...
May 11, 2022 07:00 am ET
Trevena Reports First Quarter 2022 Results and Provides Business Update
Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter ended...
May 09, 2022 07:00 am ET
Trevena to Release First Quarter 2022 Financial Results on May 11, 2022
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Apr 20, 2022 07:00 am ET
Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced results from its double blinded, crossover study...
Apr 18, 2022 07:00 am ET
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million tranche from...
Apr 13, 2022 04:05 pm ET
OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a summary of activities at recent medical...
Mar 31, 2022 07:02 am ET
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the Company entered into a royalty-based...
Mar 31, 2022 07:00 am ET
Trevena Reports Fourth Quarter and Full Year 2021 Results
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter and...
Mar 30, 2022 07:00 am ET
Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Feb 03, 2022 07:00 am ET
Trevena to Present at the 2022 BIO CEO & Investor Conference
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, will...
Jan 27, 2022 09:00 am ET
Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that China’s National Medical Products...
Jan 03, 2022 04:05 pm ET
Trevena to Participate in the Upcoming January Conferences
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry...
Dec 13, 2021 07:00 am ET
Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it is advancing TRV045 into clinical...
Nov 15, 2021 07:00 am ET
Trevena Reports Third Quarter 2021 Results
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended...
Nov 11, 2021 07:00 am ET
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the addition of Patricia Drake to its senior...
Nov 08, 2021 07:00 am ET
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Oct 13, 2021 07:00 am ET
Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two presentations at ANESTHESIOLOGY® 2021, the...
Sep 30, 2021 08:30 am ET
Thinking about buying stock in Enveric Biosciences, Dole, Virgin Galactic, Progenity, or Trevena?
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENVB, DOLE, SPCE, PROG, and TRVN.
Sep 30, 2021 07:00 am ET
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced data from 30 patients enrolled in the...
Sep 17, 2021 07:00 am ET
Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief...
Sep 09, 2021 07:00 am ET
Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief...
Aug 30, 2021 07:00 am ET
Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the acceptance of two abstracts at...
Aug 25, 2021 07:00 am ET
Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced Wake Forest Baptist Health Medical Center will...
Aug 12, 2021 07:00 am ET
Trevena Reports Second Quarter 2021 Results
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter...
Aug 10, 2021 07:00 am ET
Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of an exploratory analysis...
Aug 09, 2021 07:00 am ET
Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Jul 26, 2021 07:00 am ET
Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the first COVID-19 patient has been...
Jul 23, 2021 07:00 am ET
Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote “For” All Proposals Ahead of Special Meeting of Stockholders
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Glass Lewis and ISS, two independent,...
Jul 12, 2021 07:00 am ET
Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of the health economic model for...
Jul 08, 2021 07:10 am ET
Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in China has enrolled the...
Jul 07, 2021 07:00 am ET
Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has initiated a new study evaluating the...
Jun 28, 2021 07:00 am ET
Trevena Added to Russell 2000®, Russell 3000®, and Russell Microcap® Indexes
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has been added to the small-cap Russell 2000®...
Jun 16, 2021 08:32 am ET
Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, MannKind, Trevena, or Altimmune?
NEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CATB, ARVL, MNKD, TRVN, and ALT.
Jun 16, 2021 07:00 am ET
Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that NIDA has resumed recruiting patients for...
Jun 09, 2021 07:00 am ET
Trevena to Present at the JMP Securities Life Sciences Conference
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive...
May 19, 2021 07:00 am ET
Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the International...
May 12, 2021 07:00 am ET
Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 46th Annual...
May 06, 2021 07:03 am ET
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that TRV027, the Company’s novel AT1 receptor...
May 06, 2021 07:00 am ET
Trevena Reports First Quarter 2021 Results
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter ended...
May 05, 2021 07:00 am ET
Trevena to Release First Quarter 2021 Financial Results on May 6, 2021
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Apr 29, 2021 07:00 am ET
Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark A. Demitrack, M.D., Senior Vice President and...
Apr 21, 2021 07:00 am ET
Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that TRV027, the Company’s novel AT1 receptor...
Apr 15, 2021 07:30 am ET
Trevena, Inc. Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the AMCP 2021 Annual...
Mar 18, 2021 07:00 am ET
Trevena, Inc. Appoints Marvin H. Johnson, Jr. to Board of Directors
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Marvin H. Johnson, Jr. has been appointed...
Mar 09, 2021 07:00 am ET
Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter and...
Mar 05, 2021 07:00 am ET
Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Mar 01, 2021 07:00 am ET
Trevena, Inc. to Participate in March Virtual Investor Conferences
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in two upcoming...
Feb 22, 2021 07:00 am ET
Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will present a corporate update at the 10th...
Jan 28, 2021 07:00 am ET
Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of a new analysis of respiratory...
Jan 07, 2021 07:00 am ET
Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in two upcoming...
Jan 06, 2021 07:00 am ET
Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK™ and Announces Anticipated Pipeline Catalysts
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today provided an update on the U.S. commercial launch for...
Dec 10, 2020 08:43 am ET
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two presentations at the 59th Annual Meeting for...
Nov 20, 2020 07:00 am ET
Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication, titled “Oliceridine is Associated...
Nov 09, 2020 07:00 am ET
Trevena, Inc. to Participate in the Following November Virtual Investor Conferences
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in the...
Oct 30, 2020 09:31 am ET
Thinking about buying stock in Miragen Therapeutics, Trevena, Norwegian Cruise Line, American Resources, or Delta Air Lines?
NEW YORK, Oct. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGEN, TRVN, NCLH, AREC, and DAL.
Oct 30, 2020 07:44 am ET
Trevena, Inc. Announces DEA Scheduling of OLINVYK™ (oliceridine) injection
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that oliceridine has been classified as a...
Oct 05, 2020 07:00 am ET
Trevena, Inc. Announces Three OLINVYK™ Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced three presentations at ANESTHESIOLOGY® 2020, the...
Sep 21, 2020 07:00 am ET
Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced three presentations at the virtual 2020 American...
Sep 02, 2020 07:00 am ET
Trevena, Inc. to Present at September Virtual Investor Conferences
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in the...
Aug 26, 2020 07:00 am ET
Trevena Announces Publications of OLINVYK™ Respiratory Safety Analyses vs. IV Morphine
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two publications of the respiratory safety data...
Aug 24, 2020 07:00 am ET
Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced Imperial College London (ICL) has initiated a...
Aug 20, 2020 07:36 am ET
Trevena Announces Receipt of Milestone Payment Under Partnership in China With Jiangsu Nhwa Pharmaceutical Co.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has a received a $3 million milestone payment...
Aug 14, 2020 01:43 pm ET
Trevena to Present at the Virtual JMP Securities CNS Forum
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive...
Aug 12, 2020 09:27 am ET
Trevena Announces Pricing of $50 Million Public Offering of Common Stock
Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (“CNS”) disorders, announced today the pricing of...
Aug 11, 2020 04:01 pm ET
Trevena Announces Proposed Public Offering of Common Stock
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (“CNS”) disorders, announced today that it intends to offer and sell shares of...
Aug 10, 2020 06:30 am ET
Trevena Announces FDA Approval of OLINVYK™ (oliceridine) injection
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA)...
Aug 07, 2020 09:40 am ET
Thinking about buying stock in Trevena Inc, Plug Power, Co-Diagnostics, Cronos Group, or Snap Inc?
NEW YORK, Aug. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRVN, PLUG, CODX, CRON, and SNAP.
Aug 03, 2020 09:31 am ET
Thinking about buying stock in CymaBay Therapeutics, Trevena Inc, Co-Diagnostics, Plug Power, or Aurora Cannabis?
NEW YORK, Aug. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CBAY, TRVN, CODX, PLUG, and ACB.
Jul 29, 2020 09:31 am ET
Thinking about buying stock in Heat Biologics, IZEA Worldwide, Ocugen Inc, Trevena Inc, or Delta Air Lines?
NEW YORK, July 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTBX, IZEA, OCGN, TRVN, and DAL.
Jul 28, 2020 09:31 am ET
Thinking about buying stock in Soligenix Inc, Trip.com Group, Boxlight Corp, Trevena Inc, or Aurora Cannabis?
NEW YORK, July 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNGX, TCOM, BOXL, TRVN, and ACB.
Jun 24, 2020 09:31 am ET
Thinking about buying stock in Trevena, Translate Bio, Workhorse Group, Dynavax Technologies, or Seelos Therapeutics?
NEW YORK, June 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRVN, TBIO, WKHS, DVAX, and SEEL.
Jun 03, 2020 08:02 am ET
Trevena Announces Advancement of Oliceridine Clinical Development in China by Jiangsu Nhwa Pharmaceutical Co.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in China has been approved...
Jun 02, 2020 09:31 am ET
Thinking about buying stock in Tenax Therapeutics, Allena Pharmaceuticals, Trevena, Adaptimmune Therapeutics, or Aurora Cannabis?
NEW YORK, June 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TENX, ALNA, TRVN, ADAP, and ACB.
Jun 02, 2020 07:00 am ET
Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has entered into a collaboration with...
May 19, 2020 09:31 am ET
Thinking about buying stock in TOP Ships, General Electric, Oncolytics Biotech, Trevena, or Minerva Neurosciences?
NEW YORK, May 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TOPS, GE, ONCY, TRVN, and NERV.
May 18, 2020 09:31 am ET
Thinking about buying stock in Sorrento Therapeutics, Chesapeake Energy Corp, Trevena, Delta Air Lines, or Royal Caribbean Cruises?
NEW YORK, May 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, CHK, TRVN, DAL, and RCL.
May 07, 2020 07:00 am ET
Trevena Reports First Quarter 2020 Results
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter ended...
May 01, 2020 07:00 am ET
Trevena to Release First Quarter 2020 Financial Results on May 7, 2020
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Apr 23, 2020 07:00 am ET
Trevena Announces Publication of Comprehensive Review of Oliceridine Data
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of a review of the clinical and...
Mar 12, 2020 07:01 am ET
Trevena Reports Fourth Quarter and Full Year 2019 Results
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter and...
Mar 05, 2020 05:00 pm ET
Trevena to Report Fourth Quarter and Full Year 2019 Results on March 12, 2020
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for...
Mar 05, 2020 07:01 am ET
Trevena Announces FDA Has Set PDUFA Date of August 7, 2020 for Oliceridine
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA)...
Feb 13, 2020 07:00 am ET
Trevena Appoints Scott Applebaum as Chief Legal and Compliance Officer and SVP of Regulatory Affairs
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the appointment of Scott Applebaum as Chief...
Feb 10, 2020 07:01 am ET
Trevena Resubmits New Drug Application for Oliceridine
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has resubmitted its New Drug Application...
Feb 05, 2020 07:00 am ET
Trevena to Present at the 2020 BIO CEO & Investor Conference
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief...
Dec 23, 2019 07:00 am ET
Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a proof-of-concept study for...
Dec 12, 2019 07:00 am ET
Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 58th Annual Meeting...
Nov 20, 2019 07:00 am ET
Trevena Announces Publication of Results from Phase 3 “Real World” Safety Study for Oliceridine in The Journal of Pain Research
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced publication of results from the Phase 3...
Nov 20, 2019 07:00 am ET
Trevena Announces Publication of Results from Special Population Studies for Oliceridine
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced publication of results from two Phase 1...
Nov 18, 2019 05:05 pm ET
Trevena to Present at the Stifel 2019 Healthcare Conference
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vice President...
Nov 04, 2019 07:00 am ET
Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced topline results from its multi-dose QT study for...
Oct 21, 2019 10:30 am ET
Trevena Announces Presentations at the American Society of Anesthesiologists 2019 Annual Meeting
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) conditions, today announced four presentations at ANESTHESIOLOGY® 2019, the...
Sep 27, 2019 07:00 am ET
Trevena to Present at the 2019 Cantor Global Healthcare Conference
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced that its management team will present at the...
Sep 20, 2019 08:46 am ET
Johnson Fistel, LLP Announces Investigations of Trevena, Inc. and IVERIC bio, Inc.; Long Term Investors Encouraged to Contact the Firm
SAN DIEGO, Sept. 20, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies:
Sep 03, 2019 07:00 am ET
Trevena to Participate in Upcoming Conferences in September 2019
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced that its management team will participate in...
Aug 30, 2019 10:50 pm ET
TREVENA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Trevena, Inc. - TRVN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Trevena, Inc. (NasdaqGS: TRVN).
Aug 28, 2019 04:01 pm ET
Trevena Advances NDA Resubmission Activities for Oliceridine
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today provided an update on the activities to support...
Aug 07, 2019 07:00 am ET
Trevena Reports Second Quarter 2019 Results
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today reported its financial results for the second quarter...
Jul 31, 2019 07:00 am ET
Trevena to Report Second Quarter 2019 Results on August 7, 2019
Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced that it will release its financial results for...
Jul 19, 2019 10:50 pm ET
TREVENA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Trevena, Inc. - TRVN
NEW ORLEANS, July 19, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Trevena, Inc. (NasdaqGS: TRVN).  
Jun 27, 2019 07:00 am ET
Trevena Appoints Barry Shin as Chief Financial Officer
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced the appointment of Barry Shin as Chief...
Jun 24, 2019 07:00 am ET
Trevena Announces Publication of APOLLO-2 Results in Pain Practice
Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced publication of APOLLO-2 (pivotal Phase 3)...
Jun 20, 2019 07:00 am ET
Trevena Announces Initiation of Healthy Volunteer Study for Oliceridine
Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions, announced today that it has initiated...
May 31, 2019 10:50 pm ET
TREVENA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Trevena, Inc. - TRVN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Trevena, Inc. (NasdaqGS: TRVN).
May 29, 2019 04:01 pm ET
Trevena to Participate in Upcoming Conferences in June 2019
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System conditions, today announced that Carrie Bourdow, President and Chief...
May 10, 2019 07:00 am ET
Trevena Reports First Quarter 2019 Results
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System (CNS) conditions, today announced receipt of comments from the U.S Food...
Apr 12, 2019 08:00 am ET
AMAG Pharmaceuticals Appoints New Members to Board of Directors
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the election of two new members to its Board of Directors—Anne Phillips, M.D., senior vice president, clinical development, medical and regulatory affairs for Novo Nordisk, Inc. and Kathrine...
Apr 05, 2019 02:00 am ET
Report: Developing Opportunities within 22nd Century Group, Darling Ingredients, Silvercorp Metals, Trevena, Star Bulk Carriers, and AngioDynamics — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of 22nd Century Group, Inc (NYSE:XXII), Darling Ingredients Inc. (NYSE:DAR),...
Mar 13, 2019 07:00 am ET
Trevena Reports Fourth Quarter and Full Year 2018 Results
Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS, today reported its financial...
Mar 11, 2019 07:00 am ET
Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS, today announced publication of...
Mar 04, 2019 07:00 am ET
Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019
Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced that it will release its financial results for the fourth...
Feb 06, 2019 08:31 am ET
Thinking about buying stock in Amyris Inc., Disney, Electronic Arts, Trevena Inc. or Take-Two Interactive?
NEW YORK, Feb. 6, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMRS, DIS, EA, TRVN, and TTWO.
Feb 05, 2019 06:58 pm ET
Trevena to Present at the 21st Annual BIO CEO & Investor Conference
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced it will be featured as a presenting company at the 21st Annual...
Feb 01, 2019 08:10 am ET
Market Trends Toward New Normal in CoreLogic, Nasdaq, Nevro, Blue Apron, Unisys, and Trevena — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CoreLogic, Inc. (NYSE:CLGX), Nasdaq, Inc. (NASDAQ:NDAQ), Nevro Corp....
Jan 30, 2019 07:00 am ET
Trevena Announces $10 Million Registered Direct Offering of Common Stock
Trevena, Inc. (Nasdaq: TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused institutional investors, pursuant to which Trevena agreed to sell to the purchasers an aggregate of...
Jan 29, 2019 08:31 am ET
Thinking about buying stock in Avalon GloboCare Corp., MagneGas, Square Inc., Trevena Inc. or Verizon Communications?
NEW YORK, Jan. 29, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVCO, MNGA, SQ, TRVN, and VZ.
Jan 28, 2019 07:00 am ET
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine
Trevena, Inc. (NASDAQ: TRVN) today announced the receipt of the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the oliceridine New Drug Application (NDA)....
Dec 13, 2018 04:01 pm ET
National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology
Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced that TRV734 data were featured in a presentation at the 57th...
Dec 12, 2018 07:30 am ET
Report: Developing Opportunities within Exelixis, Cintas, BGC Partners, FirstEnergy, Hologic, and Trevena — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Exelixis, Inc. (NASDAQ:EXEL), Cintas Corporation (NASDAQ:CTAS), BGC...
Dec 10, 2018 03:13 pm ET
SHAREHOLDER ALERT: TRVN GOOG GOOGL CWH HON FIT SYF RYAAY TSRO MGI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Dec 10, 2018 11:30 am ET
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
Dec 10, 2018 10:00 am ET
SHAREHOLDER ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Trevena, Inc. (TRVN) & Lead Plaintiff Deadline - December 10, 2018
Attorney Advertising--(PR Newswire)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) and certain of its officers, on behalf of shareholders...
Dec 10, 2018 07:00 am ET
Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer
Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced the promotion of Robert T. Yoder from Vice President Commercial...
Dec 09, 2018 11:00 am ET
CLASS ACTION UPDATE for TRVN, SFIX, GOOG and CWH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Dec 07, 2018 03:55 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Trevena, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ:TRVN) of the December 10, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Dec 07, 2018 02:17 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, TRVN, GOOG, NKTR and RYAAY
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Dec 07, 2018 11:15 am ET
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ:
Dec 06, 2018 03:00 pm ET
SHAREHOLDER ALERT: JT TRVN HTHT OZK NKTR FIT GSKY ATUS PPDF MAR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Dec 06, 2018 01:00 pm ET
MONDAY DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ:
Dec 06, 2018 11:43 am ET
CLASS ACTION UPDATE for TRVN, HTHT and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Dec 05, 2018 11:07 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRVN, CWH, HON, OZK and ATUS
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Dec 04, 2018 09:02 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stitch Fix, Trevena, and Funko and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Stitch Fix, Inc., Trevena, Inc., and Funko, Inc.  Stockholders have until the deadlines listed below to petition the court to...
Dec 04, 2018 05:19 pm ET
SHAREHOLDER ALERT: TRVN HTHT DY FIT RYAAY SONS BA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Dec 04, 2018 04:33 pm ET
TRVN LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Trevena, Inc.; Important Dec. 10 Deadline - TRVN
NEW YORK, Dec. 4, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Trevena, Inc. (NASDAQ: TRVN) from May 2, 2016 through October 8, 2018, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Trevena investors under the federal securities laws.
Dec 04, 2018 02:09 pm ET
CLASS ACTION UPDATE for TRVN, SFIX and DY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Dec 04, 2018 10:00 am ET
SHAREHOLDER ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Trevena, Inc. (TRVN) & Lead Plaintiff Deadline - December 10, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) and certain of its officers, on behalf of shareholders who purchased...
Dec 03, 2018 03:25 pm ET
SHAREHOLDER ALERT: JT TRVN GOOG CWH OZK NKTR SYF AQUA GSKY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Dec 03, 2018 01:05 pm ET
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
Dec 02, 2018 12:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JT, TRVN, HTHT, CWH and HON
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 30, 2018 05:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Trevena, Inc. of Class Action Lawsuit and Upcoming Deadline – TRVN
Pomerantz LLP announces that a class action lawsuit has been filed against Trevena Inc. (“Trevena or the “Company”) (NASDAQ:  TRVN) and certain of its officers.   The class action, filed in United States District Court, Eastern District of...
Nov 30, 2018 02:04 pm ET
CLASS ACTION UPDATE for TRVN, SFIX and CWH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 29, 2018 12:09 pm ET
SHAREHOLDER ALERT: ADNT TRVN SFIX GOOG CWH OZK NKTR SYF GSKY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 28, 2018 03:41 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, TRVN, CWH, HON and DY
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 28, 2018 11:48 am ET
TREVENA INVESTOR NOTICE: Kaskela Law LLC Files Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Before Important Deadline – TRV
Kaskela Law LLC has filed a class action lawsuit against Trevena, Inc. (NASDAQ: TRVN) (“Trevena” or the “Company”) on behalf of purchasers of the Company’s securities between May 2, 2016 and October 8, 2018, inclusive (the “Class Period”)....
Nov 28, 2018 10:00 am ET
SHAREHOLDER ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Trevena, Inc. (TRVN) & Lead Plaintiff Deadline - December 10, 2018
Attorney Advertising  --  Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) and certain of its officers, on behalf of shareholders who purchased...
Nov 27, 2018 08:31 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Trevena, Camping World, and Dycom and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Trevena, Inc., Camping World Holdings, Inc., and Dycom Industries, Inc.  Stockholders have until the deadlines listed below to...
Nov 27, 2018 07:41 pm ET
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Trevena, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the December 10, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ:...
Nov 26, 2018 04:23 pm ET
CLASS ACTION UPDATE for TGTX, TRVN and DY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 26, 2018 10:47 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
Nov 25, 2018 10:00 am ET
SHAREHOLDER ALERT: MGTI TRVN HTHT IGCC FIT SYF TSRO EIX MDR ATUS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 23, 2018 06:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Trevena, Inc. of Class Action Lawsuit and Upcoming Deadline – TRVN
Pomerantz LLP announces that a class action lawsuit has been filed against Trevena Inc. (“Trevena or the “Company”) (NASDAQ:  TRVN) and certain of its officers.   The class action, filed in United States District Court, Eastern District of...
Nov 23, 2018 10:30 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HAS, CPB, ADNT, TRVN and GOOG
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 23, 2018 08:35 am ET
Investor Expectations to Drive Momentum within Capital One Financial, Trevena, CVD Equipment, Alpha Pro Tech, Horace Mann Educators, and Rubicon Technology — Discovering Underlying Factors of Influenc
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Capital One Financial Corporation (NYSE:COF), Trevena, Inc....
Nov 21, 2018 01:36 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Trevena, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ:TRVN) of the December 10, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Nov 21, 2018 10:15 am ET
CLASS ACTION UPDATE for TGTX, ALNY and TRVN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 20, 2018 04:59 pm ET
SHAREHOLDER ALERT: MGTI TRVN HTHT IGCC FIT SYF EIX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.